Moreover, TU2218, a dual inhibitor of TGFβ and VEGF, mitigates extrinsic immune suppression by restoring cytotoxic T-cell activity and reversing VEGF-induced endothelial dysfunction, thereby enhancing immunotherapy effectiveness [151]. The gene discussed is VEGFA; the disease is endothelial dysfunction.